



JFW

PATENT

Attorney Docket No.: 33846/US/2

Attorney File No.: 454892-00018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SEMPLE *et al.*

Serial No. 10/086,477

Filing Date: March 1, 2002

For: *Compositions for Stimulating Cytokine Secretion and Inducing an Immune Response*

Examiner: BURKHART, Michael D.

Art Unit: 1633 Confirmation No.: 3225

CERTIFICATE OF MAILING:

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated: September 11, 2006

Signed: 
Brent Yonohara

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163 (October 19, 2004), no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Serial No. 10/086,477
Filing Date: March 1, 2002

As far as is known to the undersigned, in accordance with 37 C.F.R. § 1.97(b)(4), this Information Disclosure Statement is being filed before the mailing of a first office action following a Request for Continued Examination under § 1.114 and therefore no fee is required.

While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 454892-00018; Our Docket No. 33846/US/2).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: 9/11/06
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
555 California Street, Suite 1000
San Francisco, CA 94104-1513
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

By: 
Todd-A.-Lorenz, Reg. No. 39,754

Attachments : Form PTO/SB/8A, Substitute for form 1449
Copies of four (4) cited references
Return Postcard



SEP 14 2002
Substitute for form 1449A/PTO
(Unmodified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	33846/US/2 (454892-00018)
-------	---	----	---	------------------------	---------------------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	AJMANI, P., et al., "3β [N-(N', N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol)-mediated gene delivery to primary rat neurons: characterization and mechanism," <i>Neurochem. Res.</i> 24(5):699-703 (May 1999).	
	C2	FILION, M., et al., "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <i>Biochim. Biophys. Acta</i> 1329(3):345-356 (Oct. 1997).	
	C3	LASIC, D., et al., "The structure of DNA - liposome complexes," <i>J. Am. Chem. Soc.</i> 119(4):832-833 (Jan. 1997).	
	C4	RÄDLER, J., et al., "Structure of DNA - cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes," <i>Science</i> 275(5301):810-814 (Feb. 1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2